Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Our group investigates the role of risk factors in the development of multiple sclerosis through functional genetic and neuro-immunological analyses, with the aim of translating these findings into a clinical utility.

Multiple sclerosis (MS) is a disabling autoimmune disease of the central nervous system, which affects approximately 0.1% of the population with variable degrees of severity. Disease susceptibility is jointly determined by genetic predisposition and environmental contribution. However, as only a handful of genetic risk factors have been investigated beyond initial genome-wide association studies and environmental factors are largely unidentified, the exact mechanism of how these associations interact remains speculative.

Our group is seeking to understand the molecular basis for these risk factors through a multidisciplinary approach, which combines analysis of both clinical samples and humanised transgenic in vivo models.

Our goal is to develop new therapeutic avenues for MS by gaining insight into disease pathways, which can be manipulated through both novel drugs and drug repositioning.